Clinical Trial Update: BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating alpelisib (BYL719) plus letrozole or exemestane in hormone-receptor-positive locally advanced unresectable or metastatic breast cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane) (exemestane)
• Femara (letrozole) (letrozole)
• Piqray (alpelisib) (alpelisib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic or Locally-advanced Unresectable Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-12-09